Estrogens plus raloxifene on endometrial safety and menopausal symptoms-semisystematic review

Menopause

Volumn 19, Issue 7, 2012, Pages 830-834

  Carneiro, Andrea Lucia Bastos ^a   De Cassia De Maio Dardes, Rita ^a   Haidar, Mauro Abi ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endometrium; Estrogen; Menopause treatment; Quality of life; Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; PLACEBO; RALOXIFENE;

ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; MONOTHERAPY; NIGHT SWEAT; PATIENT SAFETY; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS;

DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; HYPERHIDROSIS; POSTMENOPAUSE; QUALITY OF LIFE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VAGINA;

EID: 84863507564     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31824a74ce     Document Type: Review

References (18)

1. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
2. The Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Hersch AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
4. The Million Women Study Collaborative Group. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
5. The Million Women Study Collaborative Group. The Million Women Study: design and characteristics of the study population. Breast Cancer Res 1999;1:73-80.
6. Dardes RC, Jordan CV. Novel agent to modulate oestrogen action. Br Med Bull 2000;56:773-786. (Pubitemid 32042155)
7. Vogel VC, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1378.
9. Vogel VC, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.
10. O'Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002;94:274-283. (Pubitemid 34196321)
11. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150: 1897-1903.
12. Moraes AVS, Simões RS, Fonzar LF, et al. Effects of combined estrogen and raloxifene therapy on rat endometrium. Rev Bras Ginecol Obstet 2006;28:101-106. (Pubitemid 44285220)
13. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometriumVa pilot study. Menopause 2004;11: 167-175. (Pubitemid 40353234)
14. Pinkerton JV, Shifren JL, La Valleur J, et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:45-52. (Pubitemid 36706321)
15. Valiati B, Capp E, Edelweiss MI, Freitas FM, Wender MCO. Effect of raloxifene and low-dose percutaneous 17A-estradiol on menopause symptoms and endometriumVa randomized controlled trial. Maturitas 2009;62:81-84.
16. Stovall DW, Utian WH, Gass MLS, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-517.
17. Carranza-Lira S, Gooch ALM, Saldivar N, Osterwalder MS. Climateric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil 2007;52:93-96.
18. Parsons A, Merritt D, Rosen A, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352. (Pubitemid 36170137)